The fifth anniversary of clinical use of new oral anticoagulants in non-valvular atrial fibrillation
https://doi.org/10.14412/2074-2711-2015-2-4-9
Abstract
The possibilities of antithrombotic therapy for prevention of thromboembolic events in non-valvular atrial fibrillation (AF) have been significantly expanded after the development and introduction of new oral anticoagulants (NOACs) into clinical practice. Starting the clinical use of NOACs has opened a new page in oral anticoagulant therapy aimed at preventing thromboembolic events in AF. Dabigatran etexilate is the first NOAC that was registered in 2010. After completion of the RE-LY trial, the positive safety and efficacy profile of dabigatran has been confirmed in real practice of over 5 years of clinical use in more than 200,000 patients from nearly 100 countries. An observational cohort study of oral anticoagulants used in more than 134,000 patients was one of the largest independent studies of the Food and Drug Administration (FDA) in the Medicare system. In the dabigatran group, the risk of ischemic stroke, intracranial and intracerebral hemorrhage, and death was statistically significantly lower than in the warfarin group. The incidence of major and all hemorrhages requiring hospitalization, as well as myocardial infarction was comparable. Profuse gastrointestinal bleeding was more common with dabigatran. This study in the Medicare system has demonstrated a favorable benefit/risk ratio for this drug and this requires no additional changes in the current instructions and recommendations for its use.
About the Author
A. V. Fonyakin
Research Center of Neurology, Moscow, Russia 80, Volokolamskoe Shosse, Moscow 125367
Russian Federation
Russian Federation
References
1. Go AS, Hylek EM, Philips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001 May 9;285(18):2370–5.
2. Суслина ЗА, Гераскина ЛА, Фонякин АВ. Артериальная гипертония и инсульт: связь и перспективы профилактики. Атмосфера. Кардиология. 2001;(1):5–7. [Suslina ZA, Geraskina LA, Fonyakin AV. Hypertension and stroke: relationship and prospects for revention. Atmosfera. Kardiologiya. 2001;(1):5–7. (In Russ.)].
3. Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol. 2009 Dec 1;104(11):1534–9. doi: 10.1016/j.amjcard.2009.07.022.
4. Суслина ЗА, Танашян ММ, Петрова ЕА и др. Патогенетические аспекты кардиогенных ишемических инсультов. Клиническая медицина. 2001;(5):15–9. [Suslina ZA, Tanashyan MM, Petrova EA i dr. Pathogenetic aspects of cardiogenic ischemic stroke. Klinicheskaya meditsina. 2001;(5):15–9. (In Russ.)].
5. Фонякин АВ, Гераскина ЛА, Суслина ЗА. Кардиальная патология при различных патогенетических подтипах ишемического инсульта. Клиническая медицина2002; (1):25–8. [Fonyakin AV, Geraskina LA, Suslina ZA. Cardiac pathology in various pathogenic subtypes of ischemic stroke. Klinicheskaya meditsina. 2002;(1):25–8. (In Russ.)].
6. Диагностика и лечение фибрилляции предсердий. Рекомендации РКО, ВНОА и АССХ. Москва; 2012. [Diagnostika i lechenie fibrillyatsii predserdii. Rekomendatsii RKO, VNOA i ASSKh. Moskva; 2012. (In Russ.)].
7. January CT, Wann LS, Alpert JS, et al. Guideline for the Management of Patients with Atrial Fibrillation: Executive Summary. J Am Coll Cardiol. 2014;64(21):2246–80. doi: 10.1016/j.jacc.2014.03.021.
8. Hart RG, Pearce LA, Aguilar MI. Metaanalysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007 Jun 19;146(12):857–67.
9. Bousser MG. Antithrombotic agents in the prevention of ischemic stroke. Cerebrovasc is. 2009;27 Suppl 3:12–9. doi: 10.1159/000209261. Epub 2009 May 14.
10. The Medical Research Council`s General Practice Research Framework. Thrombosis revention trial: randomized trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischemic heart disease in men at increased risk. Lancet. 1998 Jan 24;351(9098):233–41.
11. Hylek EM, Skates SJ, Sheechan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for the patients with nonrheumatic atrial ibrillation. N Engl J Med. 1996 Aug 22;335(8):540–6.
12. Samsa GP, Matchar DB, Goldstein LB, et al. Quality of anticoagulation management among patients with atrial fibrillation: results of a review of medical records from 2 ommunities. Arch Intern Med. 2000 Apr 10;160(7):967–73.
13. Baker WL, Cios DA, Sander SD, Coleman CI. Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm. 009 Apr;15(3):244–52.
14. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with trial fibrillation. N Engl J Med. 2009 Sep 17;361(12):1139–51. doi: 10.1056/NEJMoa0905561. Epub 2009 Aug 30.
15. ROCKET AF Study Investigators. Rivaroxaban – once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J. 2010;159(3):340. e1–347.e1.
16. Granger CB, Alexander JH, McMurray JJ,et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011 Sep 15;365(11):981–92. doi: 10.1056/NEJMoa1107039. Epub 2011 Aug 27.
17. Парфенов ВА, Вербицкая СВ. Вторичная профилактика инсульта при фибрилляции предсердий, применение апиксабана (исследования ARISTOTLE, AVERROES). Неврология, нейропсихиатрия, психосоматика. 2014;(спецвыпуск 2):7–14. [Parfenov VA, Verbitskaya SV. Secondary prevention of stroke in atrial fibrillation, use of apixaban: ARISTOTLE, AVERROES studies. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2014;6(S2):7–14. (In Russ.)]. DOI: http://dx.doi.org/10.14412/2074-2711-2014-2S-7-14
18. You JJ, Singer DE, Howard PA, et al. Antithrombotic Therapy for atrial fibrillation. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb;141(2 Suppl):e531S–75S. doi: 10.1378/chest.11-2304.
19. Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation An update of the 2010 ESC Guidelines for the anagement of atrial fibrillation. Eur Heart J. 2012 Nov;33(21):2719–47. doi: 10.1093/eurheartj/ehs253. Epub 2012 Aug 24.
20. Furie KL, Goldstein LB, Albers GW, et al. Oral Antithrombotic Agents for the Prevention of Stroke in Nonvalvular Atrial Fibrillation: A Science Advisory for Healthcare Professionals From the American Heart Association/ American Stroke Association. Stroke. 2012 Dec;43(12):3442–53. doi: 10.1161/STR.0b013e318266722a. Epub 2012 Aug 2.
21. Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the Prevention of Stroke in Patients with Stroke and Transient Ischemic Attack. A Guideline for Healthcare Professionals from the American Heart Association/American Stroke Association. Stroke. 2014 Jul;45(7):2160–236. doi: 10.1161/STR.0000000000000024. Epub 2014 May 1.
22. Banerjee A, Lane DA, Torp-Pedersen C, Lip GY. Net clinical benefit of new oral nticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a ‘real world’ atrial fibrillation population: A modeling analysis based on a nationwide cohort study. Thromb Haemost. 2012 Mar;107(3):584–9. doi: 10.1160/TH11- 11-0784. Epub 2011 Dec 21.
23. Connoly SJ, Walentin L, Ezekowitz MD, et al. The long-term multicenter observation study of dabigatran treatment in patients with atrial fibrillation (RELY-ABLE) study. Circulation. 2013 Jul 16;128(3): 237–43. doi: 10.1161/CIRCULATIONAHA. 112.001139. Epub 2013 Jun 14.
24. Фонякин АВ. Дабигатрана этексилат при неклапанной фибрилляции предсердий в еальной практике и перспективы его применения для профилактики инсульта. Неврология, нейропсихиатрия и психосоматика. 2014;6(2):44–50. [Fonyakin AV. Dabigatran etexilate for nonvalvular atrial fibrillation in real practice and promises for its use to prevent stroke. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2014;6():44–50. (In Russ.)]. DOI: http://dx.doi.org/10.14412/2074-2711-2014-2-44-50
25. Southworth MR, Reichman ME, Under EF. Dabigatran and postmarketing reports of leeding. N Engl J Med. 2013 Apr 4;368(14):1272–4. doi: 10.1056/NEJMp1302834. Epub 2013 Mar 13.
26. Larsen TB, Rasmussen LH, Skjoth F, et al. Efficacy and safety of dabigatran etexilate and warfarin in «real world» patients with atrial fibrillation: a prospective nationwide cohort tudy. J Am Coll Cardiol. 2013 Jun 4;61(22):2264–73. doi: 10.1016/j.jacc.2013.03.020. Epub 2013 Apr 3.
27. Sorensen R, Gislason G, Torp-Pedersen C, et al. Dabigatran use in Danish atrial fibrillation patients in 2011: a national study. BMJ Open 2013; 3: e 002758.
28. Larsen TB, Gorst-Rasmussen A, Rasmussen LH, et al. Bleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillation. Am J Med. 014 Jul;127(7):650–656.e5. doi: 10.1016/ j.amjmed.2014.01.031. Epub 2014 Feb 13.
29. Larsen TB, Rasmussen LH, Gorst-Rasmussen A, et al. Myocardial ischemic events in «real world» patients with atrial fibrillation treated with dabigatran or warfarin. Am J Med. 2014 Apr;127(4):329–336.e4. doi: 10.1016/j.amjmed.2013.12.005. Epub 2013 Dec 19.
30. Larsen TB, Rasmussen LH, Gorst-Rasmussen A, et al. Dabigatran and warfarin for secondary prevention of stroke in atrial fibrillation patients: a nationwide cohort study. Am J Med. 2014 Dec;127(12):1172–8.e5. doi: 10.1016/j.amjmed.2014.07.023. Epub 2014 Sep 1.
31. Graham DJ, Reichman ME, Wernecke M, et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation. 2015 Jan 13;131(2):157–64. doi: 10.1161/CIRCULATIONAHA. 114.012061. Epub 2014 Oct 30.
Review
For citations:
Fonyakin AV. The fifth anniversary of clinical use of new oral anticoagulants in non-valvular atrial fibrillation. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2015;7(2):4-9. (In Russ.) https://doi.org/10.14412/2074-2711-2015-2-4-9
Views:
1050
Email this article 